Nilaya Varma, Co-founder and Chief Executive Officer, Primus Partners, shares his view on how geopolitical tensions are driving up input costs in India’s pharma sector due to heavy reliance on Chinese APIs and vaccine raw materials, delaying shipments and straining exports to Gulf and emerging markets